Guidance for Industry: Q3C Impurities: Residual Solvents
...cumulative method may be used to calculate the residual solvent levels in the drug product from.....5) Manufacturers of pharmaceutical products need certain information about the content of.....equal to or below that recommended in this guidance, no testing of the drug product for..
http://www.fda.gov/cber/gdlns/q3cresolvent.pdf (score=100)

MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....distribution, crystallinity, dose content uniformity, microbial content, and stability.....establish a set of criteria to which a drug substance or drug product should conform using..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=65)

þÿ
...cumulative method may be used to calculate the residual solvent levels in the drug product from.....5) Manufacturers of pharmaceutical products need certain information about the content of.....equal to or below that recommended in this guidance, no testing of the drug product for..
http://www.fda.gov/cder/guidance/Q3Cfnl.pdf (score=52)

BA/BE studies for Nasal Aerosols and Nasal Sprays for Local Ac
...information that pertains to the identity, strength,quality, purity, and potency of a drug.....test such as dose content uniformity has acceptance criteria based on repeated.....affect the BA of the drug product as a result of different solubilities and/or rates of..
http://www.fda.gov/cder/guidance/2070dft.pdf (score=42)

...These changes would simplify drug product labels and reduce the possibility of medication.....The Need for Revised Prescription Drug Labeling Although the format and content requirements for prescription drug labeling in.....Background The part of a prescription drug product's approved labeling directed to health care..
http://www.fda.gov/OHRMS/DOCKETS/98fr/122200a.htm (score=37)

IND content and format for Phase 1 studies
...As clinical development of a drug product proceeds,sponsors should discuss the manufacturing.....and the general requirements for an IND's content and format. III. CLARIFICATIONS OF.....manufacture of the investigational drug product,including both those components intended to..
http://www.fda.gov/cder/guidance/phase1.pdf (score=36)

Guidance- Content & Format CMC for Vaccine & Related Product
...A list should be provided of all components in the drug product, including drug substance(s)and.....This guidance document represents FDA's current thinking on the content and format of the.....This section should contain information on the final drug product including all drug substances..
http://www.fda.gov/cber/gdlns/cmcvacc.pdf (score=33)

/a//content.31904

http://www.fda.gov/cder/ogd/rld/17854s39.pdf (score=19)

/a//content.6074

http://www.fda.gov/cder/warn/2005/Levitra.pdf (score=18)

/a//content.21607

http://www.fda.gov/cder/dmpq/frpr7297.pdf (score=18)

/a//content.23337

http://www.fda.gov/cder/foi/appletter/2001/21335ltr.pdf (score=17)

...Conduct testing for uniform content of the finished product using an appropriate procedure or as specified in the.....Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and.....Department of Health and Human Services Food and Drug Administration Center for Drug..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0493-gdl0001.doc (score=16)

Guidance for Industry: Content and Format for Geriatric Labeling
...B If the application holder decides to resume marketing of a drug product, a geriatric labeling.....content regulations to require safety and effectiveness data for important demographic.....In cases where a drug product is unlikely to be used by the geriatric population, the..
http://www.fda.gov/cber/gdlns/gerlab.pdf (score=16)

/a//content.4998

http://www.fda.gov/cder/ogd/rld/50616s11.pdf (score=16)

International Conference on Harmonisation: Public Meeting 1/17/2002 Transcript
...So it's dangerous to give examples but, you know, for drug product quality and drug product substance, we are working on.....So we're in the process of clarifying what remains of the "Guideline for the Format and.....You could again use it up to 50 milligrams per day in a drug product, or at least that's the..
http://www.fda.gov/cder/audiences/iact/meeting_transcript_011702.htm (score=16)

Guidance for Industry Content and Format for Geriatric Labeling
...In cases where the ANDA is the reference listed drug and there is no marketed innovator drug product, the ANDA holder is responsible.....In November 2000, ICH endorsed ICH M4, which describes the content and format of a common.....B If the application holder decides to resume marketing of a drug product, a geriatric labeling..
http://www.fda.gov/cder/guidance/3636fnl.htm (score=16)

Guidance for Industry - Content and Format for Geriatric Labeling
...In cases where the ANDA is the reference listed drug and there is no marketed innovator drug product, the ANDA holder is responsible.....Format and Content of the Clinical and Statistical Sections of New Drug Applications, and.....B If the application holder decides to resume marketing of a drug product, a geriatric labeling..
http://www.fda.gov/cber/gdlns/gerlab.htm (score=16)

Guidance for Industry: Industry-Supported Scientific and Educational Activities
...of a drug or device while it is held for sale after.. umbrella of an overall regulatory.....that the company and provider agree to, the ultimate content of presentations is.....competing product, or suggest a use for.. example, be shown by labeling claims, factors..
http://www.fda.gov/cber/gdlns/sciedu.pdf (score=16)

/a//content.19839
...45 am] Research, Food and Drug Administration, persons of decisions on matters considered.....drug product, the content of a guidance.. PUBLICATION DATE: 11-2-98.. FOR FURTHER INFORMATION.....Food and Drug Administration, Implementing Section 120 of the Food and.. the Modernization..
http://www.fda.gov/cber/genadmin/120fdama.pdf (score=16)

/a//content.25365

http://www.fda.gov/cder/ogd/rld/11795s16.pdf (score=15)

Las Vegas Injury Lawyer